EP0090505A2 — Human antithrombin III, DNA sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin III, and pharmaceutical compositions comprising it
Assigned to Genentech Inc · Expires 1983-10-05 · 43y expired
What this patent protects
Human antithrombin III, and aspects concerning its preparation via recombinant DNA technology, form the basis of this disclosure. The disclosed methodology makes possible the preparation of useful quantities of the compound for applications in maintaining the fluidity of blood.
USPTO Abstract
Human antithrombin III, and aspects concerning its preparation via recombinant DNA technology, form the basis of this disclosure. The disclosed methodology makes possible the preparation of useful quantities of the compound for applications in maintaining the fluidity of blood.
Drugs covered by this patent
- Lumakras (SOTORASIB) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.